~~<i id='ADD150AAAE'><strike id='ADD150AAAE'><tt id='ADD150AAAE'><pre id='ADD150AAAE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：comprehensive 2025-09-06 02:04:35 - browse：78664

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Senators: Long

Wikipedia

hotspot

explore

focus

explore

focus

JUANMABROMATA/AFPviaGettyImagesBiosimilarsarenolongeranewanduntestedclassofmedicines.Today,theyprovi

WSS

Syphilis numbers in the United States reach record heights

CDC advisers recommend seasonal use of Pfizer RSV shot

Why you shouldn’t ask, “What country has the best health care?”

Syphilis numbers in the United States reach record heights

10 reasons why health care startups fail

Drug for rare kidney disease narrowly misses mark in clinical trial

focus

hotspot

Wikipedia

What does generative AI mean for health care? We asked experts

CommonSpirit Health keeps growing, even as it loses money

Medical records are filled with copy

How AI helped researchers track recovery from depression

Duchenne breakthrough therapy leaves behind pioneering families

10 reasons why health care startups fail

Alkermes shareholders re

Experts study whether long Covid risk adds up with each reinfection

Trump demands the U.S. pay no more for drugs than other countries … again

Philips to halt sales of sleep apnea machines in U.S.

hotspot

Investment in vaccine development is lagging, report finds

Bernie Sanders is gearing up to subpoena pharma CEOs

Medicare drug price negotiation legal challenge met with skepticism

Changes to biosimilar regulatory framework must prioritize patients

Readout LOUD podcast: possible new ALS drug, artificial wombs

Medicare drug price negotiation legal challenge met with skepticism

explore

focus

explore

focus